Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olinvacimab and Capecitabine in mCRC
NCT04751955Phase 2Withdrawn
- Sponsor
- Korean Cancer Study Group
- Start
- Jan 2022
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of olinvacimab in colorectal cancer (CRC), sponsored by Korean Cancer Study Group. Planned start Jan 2022; status: withdrawn.
02
Drugs
olinvacimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04751955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04751955.